Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer

Lee, Hyo-Sun; Lee, Yun‐Gyoo; Koo, Dong Hoe; Oh, Sukjoong; Nam, Heerim; Song, Jae-Uk; Lim, Seong Yong; Lim, Si-Young; Lee, Seung-Sei

doi:10.1007/s00280-015-2864-y

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although chemotherapy-induced neutropenia is most commonly associated with treatment of hematologic malignancies and conditioning regimens for HSCT, a number of regimens to treat solid tumors also cause neutropenia [74-77]. …”

Section: Introductionmentioning

confidence: 99%

Bacterial Pneumonia in Patients with Cancer

Wong¹,

Evans

2017

Clinics in Chest Medicine

View full text Add to dashboard Cite

Synopsis Bacterial pneumonias exact unacceptable morbidity upon patients with cancer. While the risk is often most pronounced amongst patients with treatment-induced cytopenias, the numerous contributors to life-threatening pneumonias in cancer populations range from derangements of lung architecture and swallow function to complex immune defects associated with cytotoxic therapies and graft-vs.-host disease. These structural and immunologic abnormalities often make the diagnosis of pneumonia challenging in cancer patients and impact the composition and duration of therapy. This manuscript addresses the host factors that contribute to pneumonia susceptibility, summarizes diagnostic recommendations, and reviews current guidelines for management of bacterial pneumonia in cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Bacterial Pneumonia in Patients with Cancer

Wong¹,

Evans

2017

Clinics in Chest Medicine

View full text Add to dashboard Cite

show abstract

Ifosfamide - History, efficacy, toxicity and encephalopathy

Idle

Beyoğlu

2023

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review

André

Antherieu

Boinet

et al. 2022

Cancers

View full text Add to dashboard Cite

Fatigue is a highly prevalent symptom in both cancer patients and the older population, and it contributes to quality-of-life impairment. Cancer treatment-related fatigue should thus be included in the risk/benefit assessment when introducing any treatment, but tools are lacking to a priori estimate such risk. This scoping review was designed to report the current evidence regarding the frequency of fatigue for the different treatment regimens proposed for the main cancer indications, with a specific focus on age-specific data, for the following tumors: breast, ovary, prostate, urothelium, colon, lung and lymphoma. Fatigue was most frequently reported using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) versions 3 to 5. A total of 324 regimens were analyzed; data on fatigue were available for 217 (67%) of them, and data specific to older patients were available for 35 (11%) of them; recent pivotal trials have generally reported more fatigue grades than older studies, illustrating increasing concern over time. This scoping review presents an easy-to-understand summary that is expected to provide helpful information for shared decisions with patients regarding the anticipation and prevention of fatigue during each cancer treatment.

show abstract

Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer

Abstract: In chemonaïve patients with SCLC, modified ICE is well tolerated and shows favorable efficacy.

Cited by 3 publications

References 21 publications

Bacterial Pneumonia in Patients with Cancer

Bacterial Pneumonia in Patients with Cancer

Ifosfamide - History, efficacy, toxicity and encephalopathy

Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review

Contact Info

Product

Resources

About